|  |  |  |
| --- | --- | --- |
| **Issue** | **Explanation** | **Result/response** |
| Failure to achieve intensive systolic BP target (<125 mmHg) | Number of BP drugs (or increases in drug dosing) not escalated in 17 (45.9%) patients randomised into the intensive arm | Repeat messages to investigators to intensify BP-lowering treatment |
| Failure to achieve difference of 1.0 mmol/l LDL-c between intensive and guideline groups | Third generation statins used in guideline lipid group, reflecting guideline drift. | Repeat messages sent to investigators to use guideline lipid-lowering treatment |
| Failure to achieve intensive LDL-cholesterol target (<1.3 mmol/l) | Third generation statins (atorvastatin, rosuvastatin), with or without addition of ezetimibe, not used in patients randomised into the intensive arm. | Repeat messages sent to investigators to intensify lipid-lowering treatment |
|  | Limited availability of cholestyramine |  |
| Development of dementia at lower rate than expected across the trial. | Unclear, since patients nominally at risk of developing dementia post stroke and with non-normal baseline cognition scores. | Reduced statistical power to detect treatment effects on development of dementia |